Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas R Fuerst

Showing results (11-20 of 47) with videos related to

Pageof 5
Sort By:
Viruses|May 25, 2024
Hepatitis C Virus E1E2 Structure, Diversity, and Implications for Vaccine DevelopmentBrian G Pierce, Nathaniel Felbinger, Matthew Metcalf, et al.
Molecules (Basel, Switzerland)|May 27, 2023
Fluorine-Functionalized Polyphosphazene Immunoadjuvant: Synthesis, Solution Behavior and In Vivo PotencyHarichandra D Tagad, Alexander Marin, Ruixue Wang, et al.
Clinical and Vaccine Immunology : CVI|June 15, 2012
Recombinant protective antigen anthrax vaccine improves survival when administered as a postexposure prophylaxis countermeasure with antibiotic in the New Zealand white rabbit model of inhalation anthraxElizabeth K Leffel, James S Bourdage, E Diane Williamson, et al.
New Biotechnology|December 21, 2023
Site-directed neutralizing antibodies targeting structural sites on SARS-CoV-2 spike proteinXiaofeng Li, Liudmila Kulakova, Kezzia Jones, et al.
The Journal of Biological Chemistry|March 5, 2015
Structural basis for penetration of the glycan shield of hepatitis C virus E2 glycoprotein by a broadly neutralizing human antibodyYili Li, Brian G Pierce, Qian Wang, et al.
Clinical and Vaccine Immunology : CVI|August 30, 2013
Increasing the potency of an alhydrogel-formulated anthrax vaccine by minimizing antigen-adjuvant interactionsAllan Watkinson, Andrei Soliakov, Ashok Ganesan, et al.
Biotechnology Journal|September 3, 2025
Enhanced Production of HCV E1E2 Subunit Vaccine Candidates via Protein-Protein Interaction Identification in Glycoengineered CHO CellsMina Ying Min Wu, Frances Rocamora, Caressa M Robinson, et al.
Biorxiv : the Preprint Server for Biology|June 6, 2025
Enhanced Production of HCV E1E2 Subunit Vaccine Candidates via Protein-Protein Interaction Identification in Glycoengineered CHO cellsMina Ying Min Wu, Frances Rocamora, Caressa M Robinson, et al.
Journal of Functional Biomaterials|January 24, 2025
Virus-Mimicking Polymer Nanocomplexes Co-Assembling HCV E1E2 and Core Proteins with TLR 7/8 Agonist-Synthesis, Characterization, and In Vivo ActivityThomas R Fuerst, Alexander Marin, Sarah Jeong, et al.
Biotechnology Advances|June 24, 2023
Glycosylation shapes the efficacy and safety of diverse protein, gene and cell therapiesFrances Rocamora, Angelo G Peralta, Seunghyeon Shin, et al.
Pageof 5

Showing results (11-20 of 47) with videos related to

Sort By:
Pageof 5
Viruses|May 25, 2024
Hepatitis C Virus E1E2 Structure, Diversity, and Implications for Vaccine DevelopmentBrian G Pierce, Nathaniel Felbinger, Matthew Metcalf, et al.
Molecules (Basel, Switzerland)|May 27, 2023
Fluorine-Functionalized Polyphosphazene Immunoadjuvant: Synthesis, Solution Behavior and In Vivo PotencyHarichandra D Tagad, Alexander Marin, Ruixue Wang, et al.
Clinical and Vaccine Immunology : CVI|June 15, 2012
Recombinant protective antigen anthrax vaccine improves survival when administered as a postexposure prophylaxis countermeasure with antibiotic in the New Zealand white rabbit model of inhalation anthraxElizabeth K Leffel, James S Bourdage, E Diane Williamson, et al.
New Biotechnology|December 21, 2023
Site-directed neutralizing antibodies targeting structural sites on SARS-CoV-2 spike proteinXiaofeng Li, Liudmila Kulakova, Kezzia Jones, et al.
The Journal of Biological Chemistry|March 5, 2015
Structural basis for penetration of the glycan shield of hepatitis C virus E2 glycoprotein by a broadly neutralizing human antibodyYili Li, Brian G Pierce, Qian Wang, et al.
Clinical and Vaccine Immunology : CVI|August 30, 2013
Increasing the potency of an alhydrogel-formulated anthrax vaccine by minimizing antigen-adjuvant interactionsAllan Watkinson, Andrei Soliakov, Ashok Ganesan, et al.
Biotechnology Journal|September 3, 2025
Enhanced Production of HCV E1E2 Subunit Vaccine Candidates via Protein-Protein Interaction Identification in Glycoengineered CHO CellsMina Ying Min Wu, Frances Rocamora, Caressa M Robinson, et al.
Biorxiv : the Preprint Server for Biology|June 6, 2025
Enhanced Production of HCV E1E2 Subunit Vaccine Candidates via Protein-Protein Interaction Identification in Glycoengineered CHO cellsMina Ying Min Wu, Frances Rocamora, Caressa M Robinson, et al.
Journal of Functional Biomaterials|January 24, 2025
Virus-Mimicking Polymer Nanocomplexes Co-Assembling HCV E1E2 and Core Proteins with TLR 7/8 Agonist-Synthesis, Characterization, and In Vivo ActivityThomas R Fuerst, Alexander Marin, Sarah Jeong, et al.
Biotechnology Advances|June 24, 2023
Glycosylation shapes the efficacy and safety of diverse protein, gene and cell therapiesFrances Rocamora, Angelo G Peralta, Seunghyeon Shin, et al.
Pageof 5